What does Enterome do?
Enterome develops innovative OncoMimics immunotherapies to treat cancer by leveraging insights from the microbial origins of certain autoimmune diseases.
How much did they raise?
The company raised $19M in a funding round with no specified series and without disclosed lead or participant investors. The effort was led by CEO Pierre Bélichard, focusing on advancing its Phase 1/2 trial for EO2463 OncoMimics as a potential monotherapy or combination treatment.
What are their plans for the money?
Enterome intends to use the investment to further clinical trials for EO2463 OncoMimics, aiming to address multiple forms of indolent non-Hodgkin lymphoma (iNHL) and potentially broaden its application in cancer treatment.
What have they achieved so far?
The company has already progressed to Phase 1/2 clinical trials, marking a significant milestone in its mission to develop next-generation immunotherapies for cancer.